--- title: Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates description: Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates image: https://simsendiagnostics.com/hubfs/AI-Generated%20Media/Images/The%20image%20depicts%20a%20modern%2c%20welllit%20conference%20room%20with%20large%20windows%20overlooking%20a%20vibrant%20cityscape.jpeg --- [Skip to the main content.](https://simsendiagnostics.com/news/simsen-diagnostics-announces-collaboration-with-private-cancer-center-docrates#main-content) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) Search [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIuO9gPlLEEjk7wKOX%2FoQvjPmjpfn7Vh3dvdEdQ46ksjykVejj3QtZ%2BF1YzmCJpNofmIHsIzEW4Fair%2BM647Gwny9eGoXwa%2B8APoatGKV2OCoiG5Oy7p0Fqq5Z2c7LiAtpGPFPbYfsjVuamRJjgUO5YbLU8qAipRL4cd8YfM5nGKa9DU5EetRmT0qXzuOgIoY%2FuFlQBtPE%2FzD2w5btcBBgDhCFenQ3p8og%3D&webInteractiveContentId=412216133822&portalId=25734893) Toggle Menu Search Toggle Menu [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIuO9gPlLEEjk7wKOX%2FoQvjPmjpfn7Vh3dvdEdQ46ksjykVejj3QtZ%2BF1YzmCJpNofmIHsIzEW4Fair%2BM647Gwny9eGoXwa%2B8APoatGKV2OCoiG5Oy7p0Fqq5Z2c7LiAtpGPFPbYfsjVuamRJjgUO5YbLU8qAipRL4cd8YfM5nGKa9DU5EetRmT0qXzuOgIoY%2FuFlQBtPE%2FzD2w5btcBBgDhCFenQ3p8og%3D&webInteractiveContentId=412216133822&portalId=25734893) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) [For clinical trials Pharma and CROs Validate MRD endpoints, cut trial-arm cost, build EU regulatory readiness. Design a trial assay →](https://simsendiagnostics.com/solutions-trials) [For research and labs Translational oncology See signal in paediatric and early-stage samples your current platform misses. Send samples or run SiMSen-Seq in-house. See the signal →](https://simsendiagnostics.com/solutions-research) [For clinics Premium oncology monitoring Detect minimal residual disease ahead of imaging. Logistics across the EU, UK and EEA. Detect relapse earlier →](https://simsendiagnostics.com/solutions-clinic) [Home](https://simsendiagnostics.com/) / [Company](https://simsendiagnostics.com/company-about) / [News](https://simsendiagnostics.com/news) / Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates [← Back to all news](https://simsendiagnostics.com/news) Corporate # Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates By **Camilla Hietanen** October 25, 2024, 9:45:00 AM CEST 1 min read ![](https://simsendiagnostics.com/hubfs/AI-Generated%20Media/Images/The%20image%20depicts%20a%20modern%2c%20welllit%20conference%20room%20with%20large%20windows%20overlooking%20a%20vibrant%20cityscape.jpeg) **Gothenburg 2024-10-25: Simsen Diagnostics has signed an agreement with Docrates, a private cancer center in Finland. The agreement allows Docrates to use Simsen’s personalized ctDNA analysis for patient monitoring.** Docrates, a private cancer center based in Helsinki, Finland, is the only private cancer hospital in the Nordics. It offers personalized care throughout the entire patient journey, supported by leading experts in the field to ensure the highest quality of care. As part of the Mehiläinen Group, a well-known and respected private provider of social and healthcare services, Docrates is dedicated to adopting cutting-edge innovations to meet its patients’ needs and enhance their care. Simsen Diagnostics’ solution, Simsen® Personal, is a highly sensitive, patient-specific test that detects circulating tumor DNA (ctDNA), a biomarker directly associated with the patient’s tumor. It tracks unique mutations to provide a detailed view of tumor dynamics. Using simple blood samples, the test monitors ctDNA levels over time, offering a minimally invasive way to detect even the smallest traces of cancer – potentially years before traditional methods. Docrates recognizes the potential of this technology and the advantages of personalized tests in enhancing patient care. The goal is to utilize these assays for early detection of recurring cancer and residual disease, and for monitoring treatment effectiveness, including early indicators of response or resistance. A key aspect of this collaboration is achieving faster results compared to previous efforts. By integrating Simsen® Personal into Docrates’ practice, the solution can enable more personalized and optimized patient care, ultimately improving outcomes and increasing the chances of saving lives. *“We are pleased to integrate Simsen’s ctDNA analysis into our practice. This innovative technology aligns perfectly with Docrates’ commitment to providing personalized, cutting-edge cancer care. By leveraging the power of Simsen® Personal, we enhance our ability to monitor treatment responses and detect recurrences early, which will hopefully increase available treatment options and ultimately improve outcomes for our patients. This collaboration represents a significant advancement in our mission to deliver tailored care throughout the cancer journey.”* — Dr. Juha Kononen, Chief Clinical Director, Docrates Cancer Center *“The essence of Simsen Diagnostics is our commitment to a personalized approach in everything we do, from personalized assays to personalized customer service, which is very much in line with Docrates’ approach to providing personalized care. Our collaboration brings Simsen® Personal one step closer to patients, and we couldn’t be more excited about the opportunity to potentially improve their lives.”,* — Pontus Rehn, CEO, Simsen Diagnostics. **About Docrates** At Docrates Cancer Center, patients with cancer receive personalized care under one roof throughout their treatment and follow-up period. The hospital’s operations emphasize personalized and timely cancer treatments, alongside a commitment to quality, training, and research. Docrates operates a hospital in Helsinki, Finland, with a team of over 130 cancer care professionals. As a leading private cancer hospital, Docrates is a pioneer in Europe and the only one of its kind in the Nordic countries. [https://www.docrates.com/en/](https://www.docrates.com/en/)   Docrates is part of Mehiläinen Group, a well-known and highly valued private provider of social and health care services, offering comprehensive high-quality services in Finland and internationally. Mehiläinen serves 2.1 million customers annually, and services are produced at 840 locations by more than 37,000 employees and private practitioners. Internationally, Mehiläinen provides healthcare services in Sweden, Germany, and Estonia, as well as digital healthcare software solutions through its subsidiary BeeHealthy. [https://www.mehilainen.fi/en](https://www.mehilainen.fi/en) **About Simsen Daignostics** Simsen Diagnostics is a biotech startup focusing on transforming cancer monitoring. Specialized in designing patient-specific tests, Simsen® Personal, the flagship solution, is based on ultrasensitive sequencing technology capable of detecting cancer years before standard-of-care tools. Founded in 2020, as a research spin-out from Sahlgrenska Academy, Simsen Diagnostics has experienced steady growth, gaining recognition from e.g. the pharmaceutical industry. Situated in the BioVentureHub at AstraZeneca Gothenburg, the company is at the forefront of providing innovative solutions in cancer management and monitoring. [https://simsendiagnostics.com/](https://simsendiagnostics.com/) #### Share [mailto:?subject=Simsen+Diagnostics+Announces+Collaboration+with+Private+Cancer+Center+Docrates&body=https%3A%2F%2Fsimsendiagnostics.com%2Fnews%2Fsimsen-diagnostics-announces-collaboration-with-private-cancer-center-docrates](mailto:?subject=Simsen+Diagnostics+Announces+Collaboration+with+Private+Cancer+Center+Docrates&body=https%3A%2F%2Fsimsendiagnostics.com%2Fnews%2Fsimsen-diagnostics-announces-collaboration-with-private-cancer-center-docrates) #### On this page ## More from Simsen ### [September 16, 2026, 9:52:55 AM CEST · Corporate Simsen Diagnostics to exhibit at ESMO Congress 2026 in Madrid](https://simsendiagnostics.com/news/simsen-diagnostics-esmo-congress-2026-madrid) ### [June 16, 2026, 3:23:28 PM CEST · Corporate Closing the gap between cancer research and patients is partly a question of where the test runs](https://simsendiagnostics.com/news/momentum2026-pre-event) ### [December 17, 2025, 11:57:23 AM CET · Corporate From more treatment to smarter treatment: how tumour‑informed ctDNA monitoring can reduce harm and free capacity in cancer care](https://simsendiagnostics.com/news/from-more-treatment-to-smarter-treatment-how-tumour-informed-ctdna-monitoring-can-reduce-harm-and-free-capacity-in-nordic-cancer-care) ### [November 17, 2025, 3:30:46 PM CET · Corporate Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial](https://simsendiagnostics.com/news/simsen-diagnostics-partners-with-one-carbon-pharmaceuticals-for-groundbreaking-odin-cancer-trial) Talk to us ## Running a trial or service that needs this kind of signal? Tell us about your study and your endpoints. A real scientist in CET/CEST will reply. [Request a conversation](https://simsendiagnostics.com/start-a-conversation) [Back to all news](https://simsendiagnostics.com/news) ![full\_lockup\_white\_CMYK kopia](https://simsendiagnostics.com/hs-fs/hubfs/full_lockup_white_CMYK%20kopia.png?width=166&height=45&name=full_lockup_white_CMYK%20kopia.png) **Visiting and postal address:** Pepparedsleden 1 431 53 Mölndal, Sweden **Shipping address:** c/o AstraZeneca R&D Mölndal Pepparedsleden 3 431 53 Mölndal, Sweden PLATFORM PLATFORM - [Platform overview](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) SOLUTIONS SOLUTIONS - [For clinical trials](https://simsendiagnostics.com/solutions-trials) - [For research and labs](https://simsendiagnostics.com/solutions-research) - [For clinics](https://simsendiagnostics.com/solutions-clinic) - [Solutions overview](https://simsendiagnostics.com/solutions-overview) COMPANY COMPANY - [About](https://simsendiagnostics.com/company-about) - [News](https://simsendiagnostics.com/news) - [Team](https://simsendiagnostics.com/company-team) - [Contact](https://simsendiagnostics.com/company-contact) - [Privacy policy](https://simsendiagnostics.com/legal-privacy-policy) - [Cookie Policy](https://simsendiagnostics.com/legal-cookie-policy) - [Terms of use](https://simsendiagnostics.com/legal-terms-of-use) © 2026 Simsen Diagnostics AB, All rights reserved. [Linkedin](https://www.linkedin.com/company/simsendiagnostics) Return to top ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Camilla Hietanen", "url" : "https://simsendiagnostics.com/news/author/camilla-hietanen" }, "dateModified" : "2025-01-07T10:20:40.352Z", "datePublished" : "2024-10-25T07:45:00.000Z", "headline" : "Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates", "image" : [ "https://simsendiagnostics.com/hubfs/AI-Generated%20Media/Images/The%20image%20depicts%20a%20modern%2c%20welllit%20conference%20room%20with%20large%20windows%20overlooking%20a%20vibrant%20cityscape.jpeg" ], "mainEntityOfPage" : { "@id" : "https://simsendiagnostics.com/news/simsen-diagnostics-announces-collaboration-with-private-cancer-center-docrates", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://simsendiagnostics.com/hubfs/SD_logo%20medium-2.png" }, "name" : "Simsen Diagnostics AB" } } ```